SAP India has announced that its long time customer, Lupin, has chosen to upgrade its existing SAP platform to SAP ERP 6.0.

This would enable the company to leverage their existing technology investments to ensure quality and compliance across the organization as well as support global growth plans.

The company has moved up the value chain by carving formidable market leadership positions in the Cardiovascular, CNS, Diabetes Care, Anti-Asthama and other therapy in the Anti-tuberculosis drugs and Cephalosporins space.

The company will also adopt the business intelligence platform provided by Business Objects to gain immediate access to accurate and timely business information and drive informed decision-making. SAP ERP 6.0 will further support it in consolidating its position in advanced markets across the globe, service new therapy areas & business segments, establish on-shore presence in select markets and improve operational efficiencies in core business processes while bringing down interim costs.

Commenting on the development, Kamal Sharma, Managing Director, Lupin, said, “Lupin has had an impressive & steady growth over the last 5 years; we have successfully established our presence in the advanced markets of the United States and expanded our footprint into other major markets such as the European Union, Japan, South Africa and Australia. We find an ideal partner in SAP who would provide us with the necessary technology platform to institutionalize quality assurance and compliance across diverse markets. With this upgrade to SAP ERP 6.0, we are confident that we will be able to better leverage our capabilities, and create operational efficiencies and economies of scale across segments and markets to support our global growth plans.”

Supported by the NetWeaver technology platform, SAP’s life sciences solution provides a comprehensive set of targeted applications that maximizes return on R&D investments, significantly reduces risk and exposure, increases visibility into the business and streamlines complex processes. This helps in reengineering processes into industry leading practices that in turn enable strategic business process transformation.

“The Indian Pharmaceutical industry has enjoyed phenomenal growth over the years and is a $ 4.5-billion market now.  The industry has made effective use of technology to retain competitiveness, drive business efficiency and foster innovation,” said Ranjan Das, Managing Director, SAP Indian Subcontinent.